|
1) 宮川義隆, 池田康夫. ヒト血小板増加薬開発の現況. In: 高久史麿, 溝口秀昭, 坂田洋一, 他, 編. Annual Review 2007 血液. 東京: 中外医学社; 2007. p. 230-9
|
|
|
|
|
2) 宮川義隆. トロンボポエチンとその類似化合物の作用メカニズム. Mebio Oncology. 2007; 4: 54-63
|
|
|
|
|
3) Kaushansky K. Thrombopoietin. N Engl J Med. 1998; 339: 746
|
|
|
|
|
4) Kuter DJ. New thrombopoietic growth factors. Blood. 2007; 109: 4607
|
|
|
|
|
|
5) Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002; 99: 2599
|
|
|
|
|
|
6) Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001; 98: 3241
|
|
|
|
|
|
7) Nomura S, Dan K, Hotta T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood. 2002; 100: 728-30
|
|
|
|
|
|
8) Emmons RVB, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996; 87: 4068-71
|
|
|
|
|
|
9) McMillan R, Wand L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004; 103: 1364-9
|
|
|
|
|
|
10) Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura; a double-blind randomized controlled trial. Lancet. 2008; 371: 95
|
|
|
|
|
|
11) Liem-Moolenaar M, Cerneus D, Molloy CJ, et al. Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088. Clin Pharmacol Ther. 2008; 84: 481
|
|
|
|
|
|
12) Bussel JB, Cheng G, Saleh M, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007; 357: 2237
|
|
|
|
|
|
13) McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007; 357: 2227-36
|
|
|
|
|
|
14) Desjardins RE, Tempel DL, Lucek R, et al. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood (ASH Annual Meeting Abstracts). 2006; 108: 477
|
|
|
|
|
|
15) Dziewanowska ZE, Matsumoto RD, Zhang JK, et al. Single and multiple oral doses of LGD-4665, a small molecule thrombopoietin receptor agonist, increases platelet counts in healthy male subjects. Blood (ASH Annual Meeting Abstracts). 2007; 110: 1298
|
|
|
|
|
|
16) Nogami W, Yoshida H, Koizumi K, et al. A novel, small non-peptidyl molecule butyzamide activates human thrombopoietin receptor and promotes megakaryopoiesis. Haematologica. 2008; 93: 1495
|
|
|
|
|
|
17) 宮川義隆, 中村隆典, 吉田 寛, 他. 免疫不全NOGマウスを用いたヒト巨核球・血小板造血の解析. Molecular Medicine. 2004; 41: 1487
|
|
|
|
|
|
18) Nakamura T, Miyakawa Y, Miyamura A, et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006; 107: 4300
|
|
|
|
|
|
19) Yamane A, Nakamura T, Suzuki H, et al. Interferon-alpha2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood. 2008; 112: 542-30
|
|
|
|
|
|
20) Orita T, Tsunoda H, Yabuta N. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood. 2005; 105: 562
|
|
|
|
|
|
21) Kai M, Motoki K, Yoshida H, et al. Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor. Nature Biotech. 2008; 26: 209
|
|
|
|
|
|
22) Frederickson S, Renshaw MW, Lin B, et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci U S A. 2006; 103: 14307
|
|
|
|
|